Prognostic significance of genetic variants in the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 45, Issue 11, 2010, Pages 1645-1652

  Carvalho, A ^a   Cunha, C ^a   Di Ianni, M ^a   Pitzurra, L ^a   Aloisi, T ^a   Falzetti, F ^a   Carotti, A ^a   Bistoni, F ^a   Aversa, F ^a   Romani, L ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

outcome; polymorphism; susceptibility; Th17; transplantation

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CYTOMEGALOVIRUS INFECTION; DONOR SELECTION; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; T CELL DEPLETION; TH17 CELL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 78149464264     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.28     Document Type: Article

References (40)

1. Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359: 1766-1777. (Pubitemid 351263444)
2. Carvalho A, Cunha C, Carotti A, Aloisi T, Guarrera O, Di Ianni M et al. Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplanta-tion. Exp Hematol 2009; 37: 1022-1029.
3. Granell M, Urbano-Ispizua A, Pons A, Arostegui JI, Gel B, Navarro A et al. Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation. Blood 2008; 112: 4337-4342.
4. Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S et al. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol 2007; 25: 4262-4269. (Pubitemid 47548566)
5. Dickinson AM. Non-HLA genetics and predicting outcome in HSCT. Int J Immunogenet 2008; 35: 375-380.
6. Skert C, Damiani D, Michelutti A, Patriarca F, Arpinati M, Fili C et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after Allo-SCT: results of a prospective study. Bone Marrow Transplant 2009; 44: 729-737.
7. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-852.
8. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
9. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007; 25: 221-242.
10. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-2279. (Pubitemid 44498362)
11. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccina-tion and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8: 369-377. (Pubitemid 46745412)
12. Zelante T, De Luca A, DAngelo C, Moretti S, Romani L. IL-17/Th17 in anti-fungal immunity: what's new? Eur J Immunol 2009; 39: 645-648.
13. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007; 19: 362-371. (Pubitemid 351274046)
14. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the patho-physiology of systemic lupus erythematosus. Nat Immunol 2009; 10: 778-785.
15. Mitchell P, Afzali B, Lombardi G, Lechler RI. The T helper 17-regulatory T cell axis in transplant rejection and tolerance. Curr Opin Organ Transplant 2009; 14: 326-331.
16. Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 2008; 112: 2101-2110.
17. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009; 113: 1365-1374.
18. Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009; 113: 945-952.
19. Fabrega E, Lopez-Hoyos M, San Segundo D, Casafont F, Pons-Romero F. Changes in the serum levels ofinterleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl 2009; 15: 629-633.
20. Atalar K, Afzali B, Lord G, Lombardi G. Relative roles of Th1 and Th17 effector cells in allograft rejection. Curr Opin Organ Transplant 2009; 14: 23-29.
21. Min SI, Ha J, Park CG, Won JK, Park YJ, Min SK et al. Sequential Evolution of IL-17 Responses in the early period of allograft rejection. Exp MolMed 2009; 41: 707-716.
22. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. JInfect Dis 2004; 190: 624-631. (Pubitemid 38982105)
23. Tilg H, Moschen AR, Kaser A. Suppression ofinterleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression? Eur Cytokine Netw 2009; 20: 1-6.
24. Hou W, Kang HS, Kim BS. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med 2009; 206: 313-328.
25. Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, Moretti S et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007; 37: 2695-2706. (Pubitemid 47578289)
26. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193. (Pubitemid 28482127)
27. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100. (Pubitemid 34229476)
28. Elmaagacli AH, Koldehoff M, Landt O, Beelen DW. Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplant 2008; 41: 821-826. (Pubitemid 351696347)
29. Kawaguchi M, Takahashi D, Hizawa N, Suzuki S, Matsukura S, Kokubu F et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 2006; 117: 795-801.
30. Wang JY, Shyur SD, Wang WH, Liou YH, Lin CG, Wu YJ et al. The polymorphisms of interleukin 17A (IL17A) gene and its association with pediatric asthma in Taiwanese population. Allergy 2009; 64: 1056-1060.
31. Carvalho A, Marques A, Maciel P, Rodrigues F. Study of disease-relevant polymorphisms in the TLR4 and TLR9 genes: a novel method applied to the analysis of the Portuguese population. Mol CellProbes 2007; 21: 316-320. (Pubitemid 46710343)
32. Liu Q, Thorland EC, Heit JA, Sommer SS. Overlapping PCR for bidirectional PCR amplification of specific alleles: a rapid one-tube method for simultaneously differentiating homozygotes and heterozygotes. Genome Res 1997; 7: 389-398. (Pubitemid 27183007)
33. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
34. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454. (Pubitemid 46249699)
35. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
36. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381-387. (Pubitemid 47202424)
37. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JAm Stat Assoc 1999; 94: 496-509.
38. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463. (Pubitemid 44871953)
39. Kohyama S, Ohno S, Isoda A, Moriya O, Belladonna ML, Hayashi H et al. IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17. JImmunol 2007; 179: 3917-3925.
40. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009; 114: 357-359.